GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Double Bond Pharmaceutical International AB (XSAT:DBP B) » Definitions » 3-Year FCF Growth Rate

Double Bond Pharmaceutical International AB (XSAT:DBP B) 3-Year FCF Growth Rate : 42.70% (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Double Bond Pharmaceutical International AB 3-Year FCF Growth Rate?

Double Bond Pharmaceutical International AB's Free Cash Flow per Share for the three months ended in Mar. 2025 was kr0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 42.70% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 37.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 10 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Double Bond Pharmaceutical International AB was 55.10% per year. The lowest was 3.00% per year. And the median was 20.00% per year.


Competitive Comparison of Double Bond Pharmaceutical International AB's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Double Bond Pharmaceutical International AB's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Double Bond Pharmaceutical International AB's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Double Bond Pharmaceutical International AB's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Double Bond Pharmaceutical International AB's 3-Year FCF Growth Rate falls into.


;
;

Double Bond Pharmaceutical International AB 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Double Bond Pharmaceutical International AB  (XSAT:DBP B) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Double Bond Pharmaceutical International AB 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Double Bond Pharmaceutical International AB's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Double Bond Pharmaceutical International AB Business Description

Traded in Other Exchanges
N/A
Address
Virdings Alle 32B, Uppsala, SWE, 75450
Double Bond Pharmaceutical International AB is a pharmaceutical company. The company develops and commercializes approaches for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders.

Double Bond Pharmaceutical International AB Headlines

No Headlines